Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR)
CUSIP: 61023L207
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 6,743,758
- Total 13F shares
- 3,176,497
- Share change
- +290,131
- Total reported value
- $113,304,454
- Price per share
- $35.78
- Number of holders
- 43
- Value change
- +$10,313,028
- Number of buys
- 33
- Number of sells
- 15
Quarterly Holders Quick Answers
What is CUSIP 61023L207?
CUSIP 61023L207 identifies MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 61023L207:
Top shareholders of MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
17%
|
1,134,406
|
$45,597,449 | — | 31 Mar 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
9.9%
|
599,195
|
$26,706,121 | $0 | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
8.9%
|
599,195
|
$21,816,690 | — | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
7.6%
|
511,207
|
$18,613,047 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.5%
|
168,160
|
$6,122,724 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.5%
|
100,774
|
$3,669,181 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.92%
|
62,000
|
$2,257,420 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.9%
|
60,367
|
$2,197,962 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.82%
|
55,234
|
$2,011,070 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.72%
|
48,540
|
$1,768,028 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.39%
|
25,988
|
$946,223 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.27%
|
18,480
|
$672,857 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.23%
|
15,814
|
$575,788 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.21%
|
14,464
|
$526,635 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.15%
|
10,357
|
$377,098 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.14%
|
9,161
|
$333,552 | — | 31 Mar 2025 | |
| OMERS ADMINISTRATION Corp |
13F
|
Company |
0.13%
|
9,000
|
$327,690 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.12%
|
8,228
|
$299,000 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.12%
|
8,121
|
$295,686 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.09%
|
6,141
|
$223,594 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.09%
|
5,908
|
$215,111 | — | 31 Mar 2025 | |
| GERBER, LLC |
13F
|
Company |
0.08%
|
5,601
|
$203,932 | — | 31 Mar 2025 | |
| Michael J. Brown |
3/4/5
|
Director |
—
class O/S missing
|
402,530
|
$136,941 | — | 31 Dec 2023 | |
| Andrew Paul Mazar |
3/4/5
|
Chief Scientific Officer, Director |
—
mixed-class rows
|
277,584
mixed-class rows
|
$94,434 | — | 31 Mar 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.04%
|
2,478
|
$90,224 | — | 31 Mar 2025 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.03%
|
1,761
|
$64,106 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
1,424
|
$51,848 | — | 31 Mar 2025 | |
| AlphaQuest LLC |
13F
|
Company |
0.02%
|
1,215
|
$44,238 | — | 31 Mar 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0.01%
|
600
|
$21,846 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
303
|
$11,032 | — | 31 Mar 2025 | |
| Karthik Radhakrishnan |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
126,550
mixed-class rows
|
$10,447 | — | 28 Oct 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
250
|
$9,103 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
225
|
$8,192 | — | 31 Mar 2025 | |
| Point72 (DIFC) Ltd |
13F
|
Company |
0%
|
196
|
$7,131 | — | 31 Mar 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
205
|
$7,000 | — | 31 Mar 2025 | |
| Allworth Financial LP |
13F
|
Company |
0%
|
100
|
$4,457 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
100
|
$3,641 | — | 31 Mar 2025 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
16
|
$583 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
12
|
$437 | — | 31 Mar 2025 | |
| Jose Octavio Pinto Costa Filho |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
91,500
|
— | — | 12 Jul 2021 |
Institutional Holders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) as of Q2 2025
As of 30 Jun 2025,
Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,176,497 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, ADAGE CAPITAL PARTNERS GP, L.L.C., RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc., Point72 Asset Management, L.P., ADAR1 Capital Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Affinity Asset Advisors, LLC, and STATE STREET CORP.
This page lists
43
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
34
Q2 2025 holders
43
Holder diff
9
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.